ClinConnect ClinConnect Logo
Search / Trial NCT00203853

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

Launched by UNIVERSITY OF CHICAGO · Sep 12, 2005

Trial Information

Current as of May 27, 2025

Terminated

Keywords

Hiv Haart Medication Adherance Pillbox Wristwatch

ClinConnect Summary

--Background--

The management of HIV has changed dramatically since the introduction of highly active antiretroviral therapy (HAART). HAART consists of a drug regimen that targets the virus at various points in its life cycle and is thus more effective than monotherapy. The drugs that comprise this regimen usually belong to different classes of antiretrovirals.

HAART regimens can be complex and difficult to tolerate. They usually consist of multiple pills that have to be taken two to three times a day and may also need to be taken with food, on an empty stomach or with plenty of fluids (d...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • patient must have HIV to participate
  • patient must be at least 18 years of age or older
  • must have been on HAART for six weeks
  • must have a working telephone number
  • Exclusion Criteria:
  • patient is HIV negative
  • patient is younger than 18 years of age
  • patient has been on HAART for less than 6 weeks
  • if patient does not have a working telephone number, he/she cannot participate in the study

About University Of Chicago

The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.

Locations

Chicago, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Jean-Luc Benoit, MD

Principal Investigator

University of Chicago

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials